prostate cancer
FDA Approves Nubeqa for Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved Nubeqa for metastatic castration-sensitive prostate cancer.
JUNE 6, 2025
FDA Expands Pluvicto’s Metastatic Castration-Resistant Prostate Cancer Indication
The FDA expanded the indication for(Pluvicto to include adults with PSMA-positive metastatic castration-resistant ...
APRIL 2, 2025
The Unequal Promise of Prostate Cancer Therapy
Triplet therapies that combine androgen deprivation therapy, infusion chemotherapy and oral hormones may extend the ...
AUGUST 5, 2023
Amneal Receives Approval for Leuprolide Acetate
Amneal Pharmaceuticals received abbreviated new drug application approval from the FDA for leuprolide acetate for ...
OCTOBER 30, 2022
Darolutamide Triplet Therapy Improves Survival In mHSPC
Adding the androgen receptor inhibitor darolutamide (Nubeqa, Bayer/Orion) to androgen deprivation therapy (ADT) and ...
APRIL 12, 2022
Continuing Enzalutamide After Progression and Adding Docetaxel Improved PFS in mCRPC, Study Shows
Adding docetaxel and prednisolone after progression on enzalutamide (Xtandi, Astellas) alone significantly extended ...
MARCH 25, 2022
Targeted Radioligand Therapy Approved to Treat Advanced Prostate Cancer
The FDA approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis), a targeted radioligand therapy, for ...
MARCH 25, 2022
FDA Approves Orgovyx to Treat Prostate Cancer
The FDA approved relugolix (Orgovyx, Myovant Sciences), the first oral androgen deprivation therapy for adults with ...
JANUARY 7, 2021
Lynparza Approved for Use in HRR-Mutated mCRPC
The FDA approved olaparib (Lynparza, AstraZeneca) for the treatment of adults with deleterious or suspected ...
MAY 28, 2020
Rubraca Gains Approval for Use in BRCA-Mutated mCRPC
The FDA granted accelerated approval to rucaparib (Rubraca, Clovis Oncology) for patients with deleterious BRCA ...
MAY 20, 2020
After Prostate Cancer Surgery, PSA Levels Still Key
Long-term hormone therapy can do more harm than good in men with low prostate-specific antigen (PSA) levels after ...
DECEMBER 24, 2019
Xtandi Granted New Indication: Metastatic Castration-Sensitive Prostate Cancer
The FDA has approved the use of enzalutamide (Xtandi, Pfizer/Astellas) for the treatment of patients with ...
DECEMBER 18, 2019
